GS 9674

Drug Profile

GS 9674

Alternative Names: GS-9674

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Phenex Pharmaceuticals
  • Developer Gilead Sciences
  • Class
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis

Most Recent Events

  • 14 Nov 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) prior to November 2016 , (NCT02854605)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Non-alcoholic steatohepatitis presented at the The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 11 Nov 2016 Safety and pharmacokinetics data from a phase I trial in Non-alcoholic steatohepatitis (In volunteers) presented at the The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top